Published in J Urol on March 21, 2011
Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1 | NCT01661621
The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil | NCT03144596
Initial treatment of men with newly diagnosed lower urinary tract dysfunction in the Veterans Health Administration. Urology (2013) 2.60
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur Urol (2012) 1.89
The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study. BMJ (2015) 1.50
Evaluation of voiding assays in mice: impact of genetic strains and sex. Am J Physiol Renal Physiol (2015) 1.48
Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol (2012) 1.43
Impact of 120-W 2-μm continuous wave laser vapoenucleation of the prostate on sexual function. Lasers Med Sci (2013) 1.42
Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol (2014) 1.16
Technical aspects of holmium laser enucleation of the prostate for benign prostatic hyperplasia. Korean J Urol (2013) 1.11
Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications. Clin Interv Aging (2015) 1.10
Personalized therapeutics of α₁-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Clin Interv Aging (2015) 1.07
Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol (2011) 0.98
Transurethral enucleation of the prostate versus transvesical open prostatectomy for large benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. World J Urol (2015) 0.97
Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade. Br J Pharmacol (2016) 0.92
Prevention and management of TURP-related hemorrhage. Nat Rev Urol (2011) 0.90
Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil. World J Mens Health (2013) 0.90
A randomized trial comparing thulium laser resection to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: four-year follow-up results. World J Urol (2013) 0.89
Holmium laser enucleation versus transurethral resection in patients with benign prostate hyperplasia: an updated systematic review with meta-analysis and trial sequential analysis. PLoS One (2014) 0.89
Correlation between the visual prostate symptom score and international prostate symptom score in patients with lower urinary tract symptoms. Int Neurourol J (2014) 0.88
A comprehensive review of urologic complications in patients with diabetes. Springerplus (2014) 0.88
Korean clinical practice guideline for benign prostatic hyperplasia. Investig Clin Urol (2016) 0.87
Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis. Medicine (Baltimore) (2015) 0.86
Radical prostatectomy improves and prevents age dependent progression of lower urinary tract symptoms. J Urol (2013) 0.86
Multicenter international experience of 532 nm-laser photo-vaporization with Greenlight XPS in men with large prostates (prostate volume > 100 cc). World J Urol (2017) 0.85
Risk of hospitalization for acute cardiovascular events among subjects with lower urinary tract symptoms: a nationwide population-based study. PLoS One (2013) 0.85
A survey of the FAERS database concerning the adverse event profiles of α1-adrenoreceptor blockers for lower urinary tract symptoms. Int J Med Sci (2013) 0.84
Nocturia is the Lower Urinary Tract Symptom With Greatest Impact on Quality of Life of Men From a Community Setting. Int Neurourol J (2014) 0.84
Endoscopic assessment and prediction of prostate urethral disintegration after histotripsy treatment in a canine model. J Endourol (2011) 0.84
Is there a correlation between the outcome of transurethral resection of prostate and preoperative degree of bladder outlet obstruction? Asian J Androl (2011) 0.84
Validation of a patient reported outcome questionnaire for assessing success of endoscopic prostatectomy. Prostate Int (2014) 0.84
The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. Res Rep Urol (2013) 0.83
Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation. Am J Cancer Res (2015) 0.83
Factors influencing nonabsolute indications for surgery in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: analysis using causal bayesian networks. Int Neurourol J (2014) 0.83
Medical attendance for lower urinary tract symptoms is associated with subsequent increased risk of outpatient visits and hospitalizations based on a nationwide population-based database. PLoS One (2013) 0.82
Transurethral plasmakinetic resection of the prostate is a reliable minimal invasive technique for benign prostate hyperplasia: a meta-analysis of randomized controlled trials. Asian J Androl (2015) 0.82
Recent advances in treatment for Benign Prostatic Hyperplasia. F1000Res (2015) 0.81
Single-port transvesical enucleation of the prostate for benign prostatic hyperplasia with severe intravesical prostatic protrusion. World J Urol (2011) 0.81
Transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement: a quality and meta-analysis. Int Neurourol J (2013) 0.81
Holmium laser enucleation of the prostate for treatment for large-sized benign prostate hyperplasia; is it a realistic endourologic alternative in developing country? World J Urol (2015) 0.81
Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis. PLoS One (2014) 0.81
Efficacy of a vaporization-resection of the prostate median lobe enlargement and vaporization of the prostate lateral lobe for benign prostatic hyperplasia using a 120-W GreenLight high-performance system laser: the effect on storage symptoms. Lasers Med Sci (2015) 0.81
Risk of hip fractures in men with alpha-blockers: a nationwide study base on claim registry. J Bone Metab (2015) 0.81
Involvement of magnitude of ambient temperature change in nonspecific effect in perceived placebo effect on lower urinary tract symptoms: study on switching of naftopidil in patients with benign prostatic hyperplasia. Res Rep Urol (2013) 0.81
Network Meta-Analysis of the Efficacy of Acupuncture, Alpha-blockers and Antibiotics on Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Sci Rep (2016) 0.80
Lifestyle and lower urinary tract symptoms: what is the correlation in men? Curr Opin Urol (2015) 0.80
Current status of 5α-reductase inhibitors in prostate disease management. Korean J Urol (2013) 0.80
Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One (2015) 0.80
Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population. BMC Urol (2015) 0.80
Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. Asian J Androl (2015) 0.80
An update on male hypogonadism therapy. Expert Opin Pharmacother (2014) 0.80
Alcohol, Smoking, Physical Activity, Protein, and Lower Urinary Tract Symptoms: Prospective Longitudinal Cohort. Int Neurourol J (2015) 0.79
Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: a Korean nationwide health insurance database study. Korean J Urol (2015) 0.79
Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia. Cent European J Urol (2014) 0.79
Prostate histotripsy: evaluation of prostatic urethral treatment parameters in a canine model. BJU Int (2013) 0.79
Development of Decision Support Formulas for the Prediction of Bladder Outlet Obstruction and Prostatic Surgery in Patients With Lower Urinary Tract Symptom/Benign Prostatic Hyperplasia: Part I, Development of the Formula and its Internal Validation. Int Neurourol J (2017) 0.78
Combined low-frequency ultrasound and microbubble contrast agent for the treatment of benign prostatic hyperplasia. J Endourol (2013) 0.78
Bladder Wall Thickness is Associated with Responsiveness of Storage Symptoms to Alpha-Blockers in Men with Lower Urinary Tract Symptoms. Korean J Urol (2012) 0.78
Short-, Intermediate-, and Long-term Quality of Life Outcomes Following Radical Prostatectomy for Clinically Localized Prostate Cancer. Rev Urol (2013) 0.78
Urethral-sparing histotripsy of the prostate in a canine model. Urology (2012) 0.78
Efficacy and safety of muscarinic antagonists as add-on therapy for male lower urinary tract symptoms. Sci Rep (2014) 0.78
The burden of prostatic calculi is more important than the presence. Asian J Androl (2016) 0.78
The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol (2012) 0.78
Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Ther Adv Urol (2016) 0.78
Five-Year Follow-Up Study of Transurethral Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia. J Endourol (2015) 0.78
Functional Outcomes After Transurethral Resection of the Prostate in Nursing Home Residents. J Am Geriatr Soc (2016) 0.77
(-)Doxazosin is a necessary component for the hypotensive effect of (±)doxazosin during long-term administration in conscious rats. Acta Pharmacol Sin (2013) 0.77
Effect of an employer-sponsored health and wellness program on medical cost and utilization. Popul Health Manag (2012) 0.77
Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies. Medicine (Baltimore) (2016) 0.77
Impact of a folic acid-enriched diet on urinary tract function in mice treated with testosterone and estradiol. Am J Physiol Renal Physiol (2015) 0.76
Comorbidity and nutritional indices as predictors of morbidity after transurethral procedures: A prospective cohort study. Can Urol Assoc J (2014) 0.76
Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate. Sci Rep (2015) 0.76
BPH: unmet needs in managing LUTS--a European perspective. Nat Rev Urol (2011) 0.76
The endocannabinoid system - a target for the treatment of LUTS? Nat Rev Urol (2016) 0.76
Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of α1A/α1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.76
A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol (2016) 0.76
A critical review of recent clinical practice guidelines on the diagnosis and treatment of non-neurogenic male lower urinary tract symptoms. Can Urol Assoc J (2015) 0.76
Increased Antioxidant Quality Versus Lower Quantity of High Density Lipoprotein in Benign Prostatic Hyperplasia. J Med Biochem (2015) 0.75
Transurethral surgical anatomy of the arterial bleeder in the enucleated capsular plane of enlarged prostates during holmium laser enucleation of the prostate. Int Neurourol J (2014) 0.75
Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia. BMC Urol (2013) 0.75
Management of large prostatic adenoma: Lasers versus bipolar transurethral resection of prostate. Indian J Urol (2013) 0.75
Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication. Int Neurourol J (2016) 0.75
Should Finasteride Be Routinely Given Preoperatively for TURP? ISRN Urol (2013) 0.75
Use of Medical Therapy and Success of Laser Surgery and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. Urology (2015) 0.75
Ahead of the curve. Popul Health Manag (2013) 0.75
Let's not forget about TUIP: A highly underutilized, minimally-invasive and durable technique for men with <30 g prostates. Can Urol Assoc J (2015) 0.75
Effect of transurethral split of the prostate using a double-columnar balloon catheter for benign prostatic hyperplasia: A single-center experience of 565 consecutive patients. Medicine (Baltimore) (2016) 0.75
Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study. World J Urol (2016) 0.75
Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumes. Int Braz J Urol (2015) 0.75
5-alpha-reductase inhibitor therapy postpones urine retention and prostate surgery in patients with prostate enlargement and a maximum uroflow rate of less than 15 ml/sec. PLoS One (2017) 0.75
A green and black tea extract benefits urological health in men with lower urinary tract symptoms. Ther Adv Urol (2014) 0.75
Association of serum EPCA-2 level with prostate cancer in Chinese Han population. Int J Clin Exp Pathol (2015) 0.75
Outcomes of transurethral resection and holmium laser enucleation in more than 60 g of prostate: A prospective randomized study. Urol Ann (2017) 0.75
Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature. Toxins (Basel) (2016) 0.75
Changes in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflation. J Urol (2012) 0.75
Comparison of Surgical Outcomes Between Holmium Laser Enucleation and Transurethral Resection of the Prostate in Patients With Detrusor Underactivity. Int Neurourol J (2017) 0.75
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2011) 9.75
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2014) 8.74
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst (2004) 5.84
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA (2010) 5.78
Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet (2006) 5.65
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst (2005) 5.10
A randomized trial of epidural glucocorticoid injections for spinal stenosis. N Engl J Med (2014) 5.01
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Saw palmetto for benign prostatic hyperplasia. N Engl J Med (2006) 4.99
A randomized trial comparing acupuncture, simulated acupuncture, and usual care for chronic low back pain. Arch Intern Med (2009) 4.96
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA (2006) 4.15
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med (2006) 4.09
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Defining patient complexity from the primary care physician's perspective: a cohort study. Ann Intern Med (2011) 3.83
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Screening for prostate cancer--the controversy that refuses to die. N Engl J Med (2009) 3.59
A controlled trial of web-based diabetes disease management: the MGH diabetes primary care improvement project. Diabetes Care (2003) 3.57
Video decision support tool for advance care planning in dementia: randomised controlled trial. BMJ (2009) 3.55
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology (2006) 3.34
Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia. Urology (2013) 3.31
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol (2012) 3.30
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA (2013) 3.08
Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst (2007) 3.07
How patient centered are medical decisions?: Results of a national survey. JAMA Intern Med (2013) 3.02
Do patient decision aids meet effectiveness criteria of the international patient decision aid standards collaboration? A systematic review and meta-analysis. Med Decis Making (2007) 3.02
Patient-physician connectedness and quality of primary care. Ann Intern Med (2009) 3.01
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med (2013) 2.96
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer (2002) 2.90
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol (2005) 2.84
Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol (2008) 2.84
Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol (2007) 2.84
Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med (2009) 2.82
An updated catalog of prostate cancer predictive tools. Cancer (2008) 2.82
The increasing incidence of newborn circumcision: data from the nationwide inpatient sample. J Urol (2005) 2.76
Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. Eur Urol (2009) 2.76
A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol (2006) 2.74
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol (2007) 2.70
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol (2007) 2.66
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol (2008) 2.57
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51
Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med (2004) 2.44
Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer (2006) 2.42
Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol (2003) 2.40
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia (2006) 2.39
Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol (2004) 2.39
The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care (2011) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology (2012) 2.36
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn (2012) 2.35
Stricture recurrence after urethroplasty: a systematic review. J Urol (2009) 2.34
Nocturia and quality of life: results from the Boston area community health survey. Eur Urol (2011) 2.34
HIV prevention: male circumcision comparison between a nonsurgical device to a surgical technique in resource-limited settings: a prospective, randomized, nonmasked trial. J Acquir Immune Defic Syndr (2012) 2.34
Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys (2006) 2.33
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol (2010) 2.30
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol (2012) 2.26
Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology (2011) 2.26
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol (2007) 2.24
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology. J Urol (2004) 2.23